Biocon, Sandoz partner for immunology and cancer biosimilars' development

Second large global tie-up for an Indian company after Mylan

Premium

Kiran Mazumdar-Shaw

Bengaluru

Last Updated : Jan 18 2018 | 6:44 PM IST

Biocon has signed with Sandoz, the generics arm of the $48.52-billion Swiss Pharma giant Novartis to jointly invest and co-develop, manufacture and market, a new range of biosimilars in immunology

First Published: Jan 18 2018 | 6:32 PM IST

Explore News

Stock Market Updates World Heart Day 2023 Asian Games 2023 Kabaddi schedule Latest News Live Asian Games LIVE updates India Cricket World Cup Squad Hookah Ban in Haryana Gold-Silver Price MCX Share Price Asian Games 2023 September 30 schedule

Companies News

Air India completes acquisition of its 1st A350 aircraft through GIFT City Jalan Kalrock Consortium infuses Rs 100 crore in cash-strapped Jet Airways

Sports News

Asian Games 2023 September 30 schedule: India event timings, streaming Asian Games Day 6 Highlights: Historic shot put medal push IND tally to 33

India News

Punjab farmers continue three-day 'rail roko' agitation over MSP demand War in Ukraine pushes India to obtain more self-propelled guns to arsenal

Economy News

Adani partnership remains steadfast: IHC on Adani units' stake sale Sugar market eyes restrictions from India after lower monsoon rains

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Continue

Biocon, Sandoz partner for immunology and cancer biosimilars' development

Second large global tie-up for an Indian company after Mylan

Also Read

Nod for Trastuzumab will open lot of markets: Kiran Mazumdar-Shaw

Biocon secures nod for its first biosimilar in US

Biosimilar can boost Biocon sentiment

Investors cheer Biocon progress; stock gains 230% in past two years

Biocon withdraws applications to sell two cancer drugs in Europe

Can drive in EVs in India by 2020 if infrastructure is ready: Audi

YES Bank posts 22% rise in Q3 net profit at Rs 10.76 bn; NII jumps 27%

ICICI Ventures invests Rs 1 bn in women's legwear brand Go Colors

Retail firm Siam Makro enters cash & carry biz in India, to invest Rs 10 bn

Stopping promoters' bids will severely impact recoveries: Hemant Kanoria

Explore News